This trial found that combining sacituzumab govitecan with alpelisib may help treat HER2-negative breast cancer that has spread or returned.
1 Primary · 3 Secondary · Reporting Duration: From start of study treatment until removal from study treatment; estimated 24 months maximum.
Experimental Treatment
18 Total Participants · 3 Treatment Groups
Primary Treatment: Sacituzumab govitecan · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: